



## Original Article

## Prevalence and Determinants of COPD in Spain: EPISCAN II

Joan B. Soriano<sup>a,b,\*</sup>, Inmaculada Alfageme<sup>c</sup>, Marc Miravittles<sup>b,d</sup>, Pilar de Lucas<sup>e</sup>,  
Juan José Soler-Cataluña<sup>f</sup>, Francisco García-Río<sup>b,g</sup>, Ciro Casanova<sup>h</sup>,  
José Miguel Rodríguez González-Moro<sup>i</sup>, Borja G. Cosío<sup>b,j</sup>, Guadalupe Sánchez<sup>k</sup>,  
Julio Ancochea<sup>a,b</sup>

<sup>a</sup> Servicio de Neumología, Hospital Universitario La Princesa, Universidad Autónoma de Madrid, Madrid, Spain

<sup>b</sup> Centro de Investigación en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III (ISCIII), Madrid, Spain

<sup>c</sup> Unidad de Gestión Clínica de Neumología, Hospital Universitario Virgen de Valme, Universidad de Sevilla, Sevilla, Spain

<sup>d</sup> Servicio de Neumología, Hospital Universitari Vall d'Hebron, Barcelona, Spain

<sup>e</sup> Servicio de Neumología, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain

<sup>f</sup> Servicio de Neumología, Hospital Arnau de Vilanova-Lliria, Valencia, Spain

<sup>g</sup> Servicio de Neumología, Hospital Universitario La Paz-IdiPAZ, Madrid, Spain

<sup>h</sup> Servicio de Neumología-Unidad de Investigación Hospital Universitario Nuestra Señora de La Candelaria, Universidad de La Laguna, Tenerife, Spain

<sup>i</sup> Servicio de Neumología, Hospital Universitario de Alcalá de Henares, Madrid, Spain

<sup>j</sup> Servicio de Neumología, Hospital Universitario Son Espases-IdISBa, Palma de Mallorca, Spain

<sup>k</sup> Departamento Médico, GSK, Tres Cantos, Madrid, Spain



## ARTICLE INFO

## Article history:

Received 27 May 2020

Accepted 22 July 2020

Available online 17 September 2020

## Keywords:

COPD

EPISCAN

Spain

Spirometry

## ABSTRACT

**Background:** Two previous national epidemiological studies, IBERPOC in 1997 and EPISCAN in 2007, determined the COPD burden in Spain. Changes in demographics and exposure to risk factors demand the periodic update of COPD prevalence and its determinants.

**Methods:** EPISCAN II aimed to estimate the prevalence of COPD in the general population aged 40 years or older in all 17 regions of Spain. A random population screening sample, requiring 600 participants per region performed a questionnaire plus post-bronchodilator (post-BD) spirometry.

**Results:** A total of 12,825 subjects were initially contacted, and 9433 (73.6%) agreed to participate, of whom 9092 performed a valid spirometry. Baseline characteristics were: 52.6% women, mean  $\pm$  SD age  $60 \pm 11$  years, 19.8% current- and 34.2% former-smokers. The prevalence of COPD measured by post-BD fixed ratio  $FEV_1/FVC < 0.7$  was 11.8% (95% C.I. 11.2–12.5) with a high variability by region (2.4-fold). Prevalence was 14.6% (95% C.I. 13.5–15.7) in males and 9.4% (95% C.I. 8.6–10.2) in females; according to the lower limit of normal (LLN) was 6.0% (95% C.I. 5.5–6.5) overall, by sex being 7.1% (95% C.I. 6.4–8.0) in males and 4.9% (95% C.I. 4.3–5.6) in females. Underdiagnosis of COPD was 74.7%. Cases with COPD were a mean of seven years older, more frequently male, of lower attained education, and with more smokers than the non-COPD population ( $p < 0.001$ ). However, the number of cigarettes and pack-years in non-COPD participants was substantial, as it was the reported use of e-cigarettes (7.0% vs. 5.5%) ( $p = 0.045$ ). There were also significant social and clinical differences including living alone, previous respiratory diagnoses, more comorbidities measured with the Charlson index, greater BODE and COTE scores, cognitive impairment, and depression (all  $p < 0.001$ ).

**Conclusions:** COPD remains prevalent in Spain and frequently underdiagnosed.

© 2020 SEPAR. Published by Elsevier España, S.L.U. All rights reserved.

## Prevalencia y determinantes de la EPOC en España: EPISCAN II

## RESUMEN

**Antecedentes:** Dos estudios epidemiológicos nacionales anteriores, IBERPOC en 1997 y EPISCAN en 2007, determinaron la carga de EPOC en España. Los cambios en la demografía y la exposición a factores de riesgo exigen una actualización periódica de la prevalencia de EPOC y sus determinantes.

## Palabras clave:

EPOC

EPISCAN

España

Espirometría

\* Corresponding author.

E-mail address: [jbsoriano2@gmail.com](mailto:jbsoriano2@gmail.com) (J.B. Soriano).

<https://doi.org/10.1016/j.arbres.2020.07.024>

0300-2896/© 2020 SEPAR. Published by Elsevier España, S.L.U. All rights reserved.

**Métodos:** EPISCAN II tuvo como objetivo estimar la prevalencia de EPOC en la población general de 40 años o más en las 17 Comunidades Autónomas de España. Una muestra aleatoria de población para cribado, que requirió 600 participantes por región, realizó un cuestionario y una espirometría tras la administración de un broncodilatador (post-BD).

**Resultados:** Un total de 12.825 sujetos fueron contactados inicialmente, y 9.433 (73,6%) aceptaron participar, de los cuales 9.092 realizaron una espirometría válida. Las características sociodemográficas basales fueron: un 52,6% eran mujeres, la edad media  $\pm$  DE era de  $60 \pm 11$  años, un 19,8% eran fumadores activos y un 34,2% eran exfumadores. La prevalencia de EPOC medida por el criterio de cociente fijo post-BD  $FEV_1/FVC < 0,7$  fue del 11,8% (IC 95%: 11,2–12,5) con una alta variabilidad por región (2,4 veces). La prevalencia fue del 14,6% (IC 95%: 13,5–15,7) en varones y del 9,4% (IC 95%: 8,6–10,2) en mujeres; considerando el límite inferior de la normalidad (LIN), fue del 6,0% (IC 95%: 5,5–6,5) en la muestra global y, por sexos, del 7,1% (IC 95%: 6,4–8,0) en varones y del 4,9% (IC 95%: 4,3–5,6) en mujeres. El infradiagnóstico de la EPOC fue del 74,7%. Los casos con EPOC tenían de media 7 años más, eran con mayor frecuencia varones, tenían menor nivel educativo y había más fumadores que en la población sin EPOC ( $p < 0,001$ ). Sin embargo, el número de cigarrillos y paquetes/año en los participantes que no tenían EPOC fue sustancial, como también fue elevado el uso de cigarrillos electrónicos (7,0 vs. 5,5%) ( $p = 0,045$ ). También hubo diferencias sociales y clínicas significativas que incluyeron: vivir solo, diagnósticos previos de enfermedad respiratoria, más comorbilidades medidas con el índice de Charlson, puntuaciones más altas en el índice BODE y la escala COTE, deterioro cognitivo y depresión (todos  $p < 0,001$ ).

**Conclusiones:** La EPOC sigue siendo prevalente en España y con frecuencia está infradiagnosticada.

© 2020 SEPAR. Publicado por Elsevier España, S.L.U. Todos los derechos reservados.

## Introduction

Chronic obstructive pulmonary disease (COPD) is a major cause of morbidity and mortality in the World and in Spain. Its economic impact is high, due in part to underdiagnosis that results in most patients going undetected and reaching advanced disease stages while receiving inappropriate treatment.<sup>1–3</sup> In clinical practice, the diagnosis of COPD is based on the assessment of exposure to tobacco smoke and other noxious gases, the presence of respiratory symptoms and chronic airflow limitation, documented with post-bronchodilator (post-BD) spirometry. Airflow limitation, measured by the ratio of post-BD  $FEV_1/FVC$  and other spirometric indices, provides important information for optimizing disease management and establishing severity.<sup>1,2</sup> COPD screening should be considered in any individual who presents respiratory symptoms and who has been exposed to risk factors, the most important of which is smoking.<sup>4</sup>

Two studies conducted ten years apart in Spain, IBERPOC and EPISCAN, determined a 9.1% prevalence of COPD in the general Spanish population aged 40–69 years in 1997,<sup>5</sup> and a 10.2% in the 40–80-year age range in 2007.<sup>6</sup> Other studies, such as PLATINO, found an even higher prevalence (14.3%) in various Latin American capitals, also in individuals aged over 40 years.<sup>7,8</sup> Despite these figures, COPD is still a disease with high rates of underdiagnosis: estimated rates in Spain were 78% in 1997 and 73% in 2007. The consequence is that diagnosis is made at more advanced disease stages, when the risk of exacerbations and mortality is higher.<sup>9</sup>

Global mortality estimates indicate that COPD was the fifth cause of death in 1990, and by 2010 it had already become the third cause of death,<sup>10–12</sup> so an early diagnosis is of vital importance.

A new epidemiological study was conducted to update data on the prevalence and determinants of COPD in all 17 regions in Spain.<sup>13</sup> The primary objective of EPISCAN II was to estimate the prevalence and determinants of COPD, and their distribution in the general population of Spain aged 40 years or older.

## Methods

The full protocol of EPISCAN II is based upon the EPISCAN study, and has been summarized elsewhere.<sup>12</sup> Briefly, EPISCAN II is a national, multicentre, cross-sectional, population-based epidemiological study. Study subjects were selected from the general

population of Spain who were resident in the postal code areas nearest to the participating hospitals. The 20 participating hospitals were selected from all 17 autonomous communities (regions). The inclusion criteria were as follows: men or women aged 40 years or more, resident in Spain, with no physical or cognitive difficulties that would prevent them from completing spirometry or any of the study procedures. Participants attended either a short- or long-visit in the hospital centre. The study population was divided into two cohorts, depending on the results of the post-BD spirometry: patients with COPD ( $FEV_1/FVC < 0.7$ ) and non-COPD individuals ( $FEV_1/FVC \geq 0.7$ ).

Field work was undertaken from April 2017 to February 2019. The study was approved by the ethics committee (EC) of each of the participating centres, with the EC of the Hospital Universitario La Princesa acting as the reference committee. All participants signed an informed consent. The EPISCAN II protocol is registered at <https://clinicaltrials.gov> with the No. NCT03028207 and at [www.gsk-clinicalstudyregister.com/study/205932](http://www.gsk-clinicalstudyregister.com/study/205932).

### Selection of participants

Study sampling was conducted using a pre-selected list of the post codes closest to each hospital. A list of random telephone numbers was obtained, stratified according to these post codes and quotas for sex and age groups, all according to the latest EU directives on data protection and privacy.<sup>14,15</sup>

### Variables and procedures

During the first telephone call, the subject was informed about confidentiality and data protection, and if they agreed to respond, they were asked questions about their cohabitants, confirmation of the post code for assignment of the nearest hospital, previous diagnoses of respiratory disease (chronic bronchitis, emphysema, COPD, or asthma), smoking habit (smoker and number of cigarettes, never-smoker, former smoker and number of cigarettes) and presence of cough or expectoration. During the second telephone call, conducted by the investigator from the hospital, a survey was administered with questions on the previous diagnosis of respiratory diseases, smoking habit, and the presence of other symptoms associated with COPD. The variables collected during the visit with the healthcare professional provided a comprehensive profile of




Fig. 1. STROBE flow diagram of participants and non-participants in EPISCAN II until spirometry (short visit) and low-dose CT scan (long visit).

both non-COPD individuals who were selected for the study visit, and, in particular, participants in the COPD group.

Information were collected on age, sex, level of education, family conditions, weight and height, and conventional use of tobacco (cigarettes, pipe, cigar) or use of other modes of delivery (electronic cigarette, chewing tobacco, etc.).

Other questionnaires included: COPD Assessment Test (CAT); Hospital anxiety and depression scale (HADS); Yale Physical Activity Questionnaire (YPAS); European Coal and Steel Community Questionnaire on respiratory symptoms; Questions on exposure to dust and fumes in the workplace; Mini-Mental State Questionnaire (administered only to participants 60 years of age or older); Fagerström test; and Prochaska's Stages of Change.

Lung Function and Clinical Tests conducted for the entire sample included: Baseline pulse oximetry; Forced spirometry; and assessment of multicomponent indices and comorbidities.

#### Lung function and clinical tests (for the entire sample)

Baseline pulse oximetry was determined using a Pulsox 300i (Konica-Minolta, Japan) pulse oximeter and the fraction of carbon monoxide (CO) in exhaled air was determined with aco-oxymeter (MicroCO, Carefusion, UK).

Forced spirometry was performed using a pneumotachograph (Vyntus Spiro, Carefusion, Germany), according to standardized procedures as indicated by SEPAR guidance<sup>16</sup> and Global Lung Function Initiative (GLI) equations were used as reference value.<sup>17</sup> Bronchodilator test was conducted with the inhalation of 400 µg salbutamol. According to the ATS/ERS guidelines,<sup>18</sup> criteria for bronchodilation were an increase in FVC or FEV<sub>1</sub> > 200 ml and greater than 12% compared to the baseline value. Only spirometries with quality grades A–C were accepted for analysis.<sup>15</sup> Airflow limitation was defined as a postbronchodilator FEV<sub>1</sub>/FVC ratio < 0.7 (or alternatively also expressed as an FEV<sub>1</sub>/FVC < lower limit of normal (LLN)). Underdiagnosis of COPD by age, sex and area was defined as the percentage of those not reporting a previous diagnosis of COPD, chronic bronchitis or emphysema among those with airflow limitation.

#### Multicomponent indices and comorbidities

In order to have a better characterization of the population, comorbidities were quantified by means of: the Charlson index (19 comorbidities)<sup>19</sup>; the COTE index (12 comorbidities)<sup>20</sup>; and previous diagnosis of other respiratory diseases. As multicomponent indices, BODE and BODEx were calculated.<sup>21</sup>

#### Statistical analysis

According to data from the 2011 Census of Population and Dwellings, published by the National Institute of Statistics,<sup>22</sup> the population of Spain aged 40 years or more comprises 23,957,645 individuals. Taking into account the 10.2% prevalence of COPD found in the EPISCAN study,<sup>6</sup> an a priori sample size calculation estimated with an accuracy of ±0.6% and a 10% dropout rate, that approximately 10,200 eligible individuals were needed to be included in the study. Therefore, between 300 and 600 participants (150–300 men and 150–300 women) were included in each site. The geographic information system inverse distance weighted (IDW) interpolation technique was used for mapping the spatial distribution of epidemiological variables.<sup>23</sup> The statistical and analysis plan are available elsewhere.<sup>13</sup> A level of significance of 0.05 was used for all statistical tests performed on the study variables.

#### Results

Overall, a total of 12,825 subjects were initially contacted by phone, and 9433 (73.6%) agreed to be seen in the hospital, as per Fig. 1. The final sample of 9092 participants, compared to non-participants was on average two years younger, less frequently women, less frequently diagnosed of COPD, chronic bronchitis or emphysema, but more frequently diagnosed of asthma (all  $p < 0.001$ ); on smoking exposure, the percentage of current smokers was similar, although with more ex-smokers, and overall consumed more pack-years ( $p = \text{all } p < 0.001$ ) (data not shown).

Out of 9433 subjects included and seen in hospital, 9092 (96.4%) performed valid spirometry (A, B or C quality), and represent an overall response rate of 70.9%. Baseline characteristics of participants were: 52.6% women, mean ± SD age 60.2 ± 11.1 years, 19.8% current smokers and 34.2% former smokers (Table 1).

#### Clinical and COPD characteristics

As per the primary analysis, 1077 out of 9092 participants were considered COPD, while 8015 were not, with a prevalence of 11.8% (95% C.I. 11.2–12.5). By sex, prevalence was 14.6% (95% C.I. 13.5–15.7) in males and 9.4% (95% C.I. 8.6–10.2) in females.

Cases with COPD were a mean of seven years older, less frequently female (41.6% vs. 54.1%), of lower attained education, and were more frequently current- and former-smokers than controls ( $p < 0.001$ ), although the number of cigarettes and pack-years in

**Table 1**  
Demographic and clinical characteristics of EPISCAN II COPD and non-COPD participants.

	COPD (n = 1077)	Non-COPD (n = 8015)	All (n = 9092)	p
Gender, women, n (%)	448 (41.6)	4333 (54.1)	4781 (52.6)	<0.0001
Age, mean ± SD	66.5 ± 10.9	59.4 ± 10.8	60.2 ± 11.1	<0.0001
BMI, mean ± SD	27.4 ± 4.8	27.5 ± 5.0	27.5 ± 5.0	0.5482
Smoking history, n (%)				<0.0001
Smoker	333 (30.9)	1465 (18.3)	1798 (19.8)	
Ex-smoker	453 (42.1)	2659 (33.2)	3112 (34.2)	
Never smoker	291 (27.0)	3891 (48.5)	4182 (46.0)	
Pack-years (smokers and ex-smokers)	39.4 ± 28.1	23.8 ± 20.9	26.3 ± 22.9	<0.0001
Use of e-cigarettes, n (%)	55 (7.0)	215 (5.2)	270 (5.5)	0.0450
Education, n (%)				<0.0001
Less than primary school	41 (3.8)	141 (1.8)	182 (2.0)	
Primary school	284 (26.4)	1658 (20.7)	1942 (21.4)	
Secondary school	262 (24.3)	1729 (21.6)	1991 (21.9)	
University degree	485 (45.0)	4455 (55.6)	4940 (54.3)	
Lives alone, n (%)	211 (19.6)	1197 (14.9)	1408 (15.5)	<0.0001
Spirometry (post-BD), mean ± SD				
FVC (L)	3.5 ± 1.1	3.7 ± 1.0	3.6 ± 1.0	<0.0001
FVC (%)	99.4 ± 18.3	101.3 ± 14.4	101.0 ± 14.9	<0.0001
FEV <sub>1</sub> (L)	2.2 ± 0.8	2.9 ± 0.8	2.9 ± 0.8	<0.0001
FEV <sub>1</sub> (%)	80.5 ± 18.7	103.3 ± 15.0	100.6 ± 17.1	<0.0001
FEV <sub>1</sub> /FVC	62.5 ± 7.9	80.3 ± 4.9	78.2 ± 7.8	<0.0001
FEV <sub>6</sub> (L)	3.3 ± 1.0	3.6 ± 1.0	3.6 ± 1.0	<0.0001
FEV <sub>6</sub> (%)	94.7 ± 17.2	101.3 ± 14.2	100.6 ± 14.7	<0.0001
Quality of spirometry, n (%)				0.0013
A	845 (78.5)	5900 (73.6)	6745 (74.2)	
B	202 (18.8)	1905 (23.8)	2107 (23.2)	
C	29 (2.7)	210 (2.6)	239 (2.6)	
Missing, n	1	0	1	
Dyspnoea MRC, n (%)				<0.0001
0	539 (50.1)	6097 (76.3)	6636 (73.2)	
I	373 (34.7)	1601 (20.0)	1974 (21.8)	
II	116 (10.8)	232 (2.9)	348 (3.8)	
III	41 (3.8)	59 (0.7)	100 (1.1)	
IV	6 (0.6)	2 (0.01)	8 (0.1)	
Previous Dx of COPD, CB or E, n (%)	273 (25.3)	208 (2.6)	481 (5.3)	<0.0001
Chronic cough, n (%)	311 (30.0)	1089 (14.0)	1400 (15.9)	<0.0001
Expectoration, n (%)	288 (27.7)	858 (11.0)	1146 (13.0)	<0.0001
Wheezing, n (%)	583 (54.8)	2435 (30.9)	3018 (33.7)	<0.0001
CAT score, mean ± SD	9.07 (6.78)	5.99 (5.56)	6.36 (5.81)	<0.0001
Previous Dx of asthma, n (%)	182 (16.9)	535 (6.7)	717 (7.9)	<0.0001
Charlson comorbidity index	0.68 ± 1.16	0.31 ± 0.82	0.36 ± 0.87	<0.0001
COTE index	1.22 ± 2.46	0.98 ± 2.22	1.01 ± 2.25	0.0010
Mini-Mental MEC <sup>a</sup> < 30, n (%)	25 (3.7)	90 (2.7)	115 (3.0)	0.0324
Anxiety HADS, n (%)				0.4112
No (0–7)	770 (72.6%)	5831 (73.5)	6601 (73.4)	
Possible anxiety (8–10)	177 (16.7%)	1206 (15.2)	1383 (15.4)	
Probable anxiety (11–21)	113 (10.7%)	895 (11.3)	1008 (11.2)	
Missing, n	17	83	100	
Depression HADS, n (%)				0.0010
No (0–7)	910 (85.5)	7092 (89.3)	8002 (88.9)	
Possible depression (8–10)	107 (10.1)	577 (7.3)	684 (7.6)	
Probable depression (11–21)	47 (4.4)	271 (3.4)	318 (3.5)	
Missing, n	13	75	88	

CB (chronic bronchitis) or E (emphysema).

<sup>a</sup> The Mini-Mental MEC questionnaire was applied only in those participants 60 years and older; a cut-off score lower than 30 in the MEC questionnaire is considered positive of suspected cognitive impairment.

non-COPD participants was substantial (Table 1); reported use of e-cigarettes, (7.0% vs. 5.5%) was significantly different (0.0450). There were also significant differences versus participants without COPD in all respiratory and other clinical variables, including living alone, previous respiratory diagnoses, respiratory symptoms, more comorbidities with the Charlson index, greater BODE and COTE scores, cognitive impairment, and depression HADS (all  $p < 0.001$ ), except for BMI ( $p = 0.5482$ ) and Anxiety HADS ( $p = 0.4112$ ).

#### Lung function and COPD underdiagnosis

As expected, COPD prevalence increased by age in both men and women, and the greatest prevalence was observed in those 80 years and older, with a prevalence of 26.1% (95% C.I. 20.9–31.9) in women and of 34.7% (95% C.I. 28.1–41.6) in men (Fig. 2). There was a high variability (2.4-fold) among the 17 regions, with a minimum prevalence of 7.1% in Asturias and a maximum of 17.3% in Catalonia (Table 2 and Fig. 3). Estimates of the prevalence of COPD according




Fig. 2. Prevalence of COPD by age and sex according to the fixed ratio FEV<sub>1</sub>/FVC < 0.7 or the lower limit of normal (LLN) in: A) Women and B) Men.

Table 2


Variability of the prevalence of airflow limitation by Autonomous Community (region), measured as a fixed ratio and as LLN, total and by sex.

	Prevalence of COPD by Fixed Ratio			Prevalence of COPD by LLN		
	All n (%)	Female %	Male %	All n (%)	Female %	Male %
Andalucía	49 (8.5)*	6.7	10.2	22 (3.8)	2.5	5.1
Aragón	75 (12.6)	10.7	14.5	36 (6.0)	5.7	6.4
Asturias	41 (7.1)*	5.2*	9.1*	16 (2.8)*	2.1	3.5*
C.Valenciana	50 (10.4)	9.1	12.1	27 (5.6)	5.5	5.8
Cantabria	67 (11.3)	7.6	15.2	34 (5.7)	4.6	6.9
C.La Mancha	55 (9.7)	6.4	13.0	32 (5.7)	3.2	8.1
C.-León	65 (10.7)	8.8	13.8	32 (5.3)	2.9	9.1
Catalunya	103 (17.3)*	11.9	22.7*	47 (7.9)	5.4	10.3
Extremadura	96 (16.9)*	12.7	21.1*	49 (8.6)	7.4	9.8
Galicia	92 (16.8)*	10.2	22.8*	46 (8.4)	5.3	11.2
Illes Balears	66 (11.1)	8.5	13.6	33 (5.6)	3.5	7.5
I. Canarias	34 (11.1)	8.9	14.9	17 (5.6)	6.3	4.4
La Rioja	51 (9.6)	7.6	11.7	28 (5.2)	4.0	6.6
Madrid	84 (14.0)	16.6*	11.5	46 (7.7)	9.1	6.3
Murcia	55 (9.4)	8.2	10.5	31 (5.3)	5.5	5.1
Navarra	66 (13.5)	12.3	16.0	32 (6.6)	6.4	6.8
País Vasco	28 (10.1)	6.0	16.5	16 (5.8)	5.4	6.4
<b>TOTAL</b>	<b>1077 (11.8)</b>	<b>9.4</b>	<b>14.6</b>	<b>544 (6.0)</b>	<b>4.9</b>	<b>7.1</b>

\* Prevalence of COPD by fixed ratio (FEV<sub>1</sub>/FVC < 0.7) or by LLN (lower limit of normal); p < 0.05 compared with total.

to the LLN were 6.0% (95% C.I. 5.5–6.5) overall, by sex being 7.1% (95% C.I. 6.4–8.0) in males and 4.9% (95% C.I. 4.3–5.6) in females (Table 2). Underdiagnosis of COPD was 74.7%, higher in women than in men (80.6% vs. 70.4%, p < 0.001), yet again with a high variability by region (Table 3). However, COPD overdiagnosis was overall low

(2.6%). Underdiagnosis of COPD measured by the LLN was 61.0%, again higher in women than in men (78.4% vs. 68.6%, p < 0.001), yet again with a high variability by region. However, according to the LLN there were no statistically significant differences in the autonomous communities compared to the total (Table 3).



**Fig. 3.** Map of the prevalence of airflow limitation in Spain by Autonomous Community, measured as a fixed ratio in (A) women; and (B) men.

## Discussion

### Main findings

Adhering to the compromise in global health agendas of an expanded emphasis on non-communicable diseases, sound evidence on trends and determinants of COPD at the national and international levels are essential. In here, EPISCAN II updates previous findings and includes new estimates and trends on COPD prevalence in Spain. The confirmation that COPD is one of the most prevalent conditions (more than one in ten) in the general population, found in all ages from young adults to the very elderly, and that is more frequent in men but with an increasing burden in women, yet with a regional variability (2.4-fold) of a similar magnitude than asthma,<sup>24</sup> will set ground for further Public Health

interventions. Note that a previous diagnosis of asthma was two-fold higher in those with COPD (16.9%) than without (6.7%) in this study. Regrettably our efforts to reduce COPD underdiagnosis, appear not enough, as three out of four individuals with objective airflow limitation compatible with COPD reported no medical diagnosis previously, therefore suffering unnecessary individual and population burden, as COPD is considered a preventable and treatable disease.<sup>2</sup>

### Previous literature

The so-called shoe-leather epidemiology<sup>25</sup> is essential to monitor trends of chronic diseases, as populations change, but diseases and risk factors also change.<sup>26</sup> Direct comparison with previous estimates of spirometry in Spain will require of further analyses,<sup>27</sup>



**Table 3**

Variability of the under diagnosis of COPD by Autonomous Community (region), measured as a fixed ratio and as LLN, total and by sex.

	Underdiagnosis of COPD by fixed ratio			Underdiagnosis of COPD by LLN		
	All n (%)	Female n (%)	Male n (%)	All n (%)	Female n (%)	Male n (%)
Andalucía	39 (79.6)	16 (84.2)	23 (76.7)	17 (77.3)	7 (100)	10 (66.7)
Aragón	57 (76.0)	29 (90.6)	28 (65.1)	25 (69.4)	16 (94.1)	9 (47.4)
Asturias	32 (78.0)	14 (93.3)	18 (69.2)	9 (56.3)	6 (100)	3 (30.0)
C.Valenciana	37 (74.0)	19 (76.0)	18 (72.0)	20 (74.1)	13 (86.7)	7 (58.3)
Cantabria	47 (70.1)	17 (73.9)	30 (68.2)	21 (61.8)	11 (78.6)	10 (50)
C.La Mancha	48 (87.3)	18 (100.0)	30 (81.1)	28 (87.5)	9 (100)	19 (82.6)
C.-León	57 (87.7)	30 (90.9)	27 (84.4)	25 (78.1)	9 (81.8)	16 (76.2)
Catalunya	83 (80.6)	30 (85.7)	53 (77.9)	36 (76.6)	13 (81.3)	23 (74.2)
Extremadura	79 (82.3)	32 (88.9)	47 (78.3)	35 (71.4)	17 (81.0)	18 (64.3)
Galicia	67 (72.8)	20 (74.1)	47 (72.3)	30 (65.2)	9 (64.3)	21 (65.6)
Illes Balears	47 (71.2)	20 (83.3)	27 (64.3)	18 (54.5)	8 (80.0)	10 (43.5)
I. Canarias	24 (70.6)	10 (58.8)	14 (82.4)	10 (58.8)	6 (50.0)	4 (80.0)
La Rioja	21 (41.2)*	12 (57.1)	9 (30.0)*	12 (42.9)	6 (54.5)	6 (35.3)
Madrid	57 (67.9)	38 (77.6)	19 (54.3)	32 (69.6)	23 (85.2)	9 (47.4)
Murcia	47 (85.5)	23 (95.8)	24 (77.4)	27 (87.1)	15 (93.8)	12 (80.0)
Navarra	45 (68.2)	28 (70.0)	17 (65.4)	18 (56.3)	12 (57.1)	6 (54.5)
País Vasco	17 (60.7)	5 (50.0)	12 (66.7)	10 (62.5)	5 (55.6)	5 (71.4)
<b>TOTAL</b>	<b>804 (74.6)</b>	<b>361 (80.6)</b>	<b>443 (70.4)</b>	<b>373 (68.6)</b>	<b>185 (78.4)</b>	<b>188 (61.0)</b>

\*  $p < 0.05$  compared with total.

as age thresholds differ, spirometers and guidelines have changed, and even interpretation of respiratory manoeuvres has evolved.<sup>28</sup> However, compared with the first EPISCAN, an increase of COPD in women is seen in the overlapping age strata from age 50 years and onwards (3.2% vs 3.2% in 40–49 yrs., 4.5% vs 6.6% in 50–59 yrs., 7.6% vs 10.0% in 60–69 yrs., and 10.8% vs 14.5% in 70–79 yrs.), which is a new reminder of the growing toll of women catching up with men in cigarette smoking.<sup>29</sup> Of note, Spain is considered to be in phase IIIb of the tobacco epidemic,<sup>30</sup> but new forms of smoking, including the health effects of vaping and heat-not-burn products such as IQOS,<sup>31</sup> should be actively assessed. Our finding of reported use of e-cigarettes, in 7.0% of COPD cases but also in 5.5% of non-COPD participants is worrying.<sup>32</sup> Exploring the asthma and COPD overlap,<sup>33</sup> or those with preserved ratio impaired spirometry (PRISm), alternatively known as restrictive, unclassified spirometry,<sup>34</sup> are just a few of the pre-established analyses scheduled with EPISCAN II,<sup>12</sup> all beyond the scope of this manuscript.

Our finding of a 74.7% underdiagnosis of COPD in Spain should be put into perspective, as it is no better than the 73% in 1997,<sup>5</sup> and only marginally different than the 78% seen in 2007<sup>6</sup>; these are unwelcome news in our global effort to reduce COPD unmet burden,<sup>4,35</sup> where new strategies might be field tested and then implemented.<sup>36</sup> The 80.6% underdiagnosis in Spanish women, ten points higher than the 74.6% observed in men, confirms previous findings of higher female underdiagnosis in Spain, which is at odds with observations elsewhere, where male COPD underdiagnosis prevails, and to date its reasons appear elusive.<sup>37</sup> There were substantial differences in the variability of COPD underdiagnosis by Autonomous Community, total, and by sex, with percentages ranging from the 35% only in men in La Rioja and up to 100% in women in Castilla-La Mancha (Table 3). Given that a common protocol was identical in all sites, and that these findings might be outlier values but not errors, the determinants of these differences will be specifically explored in already planned analyses of EPISCAN II. However, for the record indeed La Rioja has an advanced system of COPD screening according to the National Strategy,<sup>38</sup> and they apply a near systematic population case-finding and screening.

There are few studies that “medicalize” new COPD diagnoses (or airflow limitation) after a population spirometric study.<sup>39,40</sup> Perhaps the most relevant is the one by Llordés et al.<sup>41</sup> They conducted spirometry in 1738 population smokers aged 45 years or older. All those newly diagnosed with COPD, defined as post-BD FEV<sub>1</sub>/FVC < 0.7, were tested with a 4-week treatment with

formoterol and budesonide. The prevalence of COPD was 24.3% (95% CI 22.3–26.4), with an overall underdiagnosis of 56.7%. After 4 weeks of treatment, 16% of initially obstructed patients had normal spirometry; in addition, 15.6% of individuals with a diagnosis of COPD did not sustain airflow obstruction, while 84.4% did.

#### Strengths and limitations

EPISCAN II has several strengths, as it is consistent and even surpasses previous studies in Spain (IBERPOC and EPISCAN),<sup>5,6</sup> namely: By assessing all 17 regions in Spain, we were able to produce a complete map of the distribution of COPD and its determinants for the first time. We did not establish an upper age limit for surveying, as population growth and ageing, particularly affecting women, is a global trend<sup>42</sup>; high quality spirometry was applied to nearly 10,000 individuals, that was centrally monitored for quality, and adhered to the strictest international guidance and protocols, as with all other measurements. Indeed, the oldest participant in EPISCAN II was a woman aged 98 years old from Extremadura, with spirometry quality graded B. Given the large sample size and high response rate, it can be considered that the final sample of participants is representative of the Spanish population older than 40 years.

However, a number of limitations are worth considering: Most areas surveyed were urban, and although 90%+ of the Spanish population live in cities, the unmet burden in rural areas is expected to be high but under-represented in here.<sup>2</sup> Like all COPD epidemiological studies, diagnosis is based solely on spirometry (airflow limitation) and this may cause other obstructive diseases than COPD itself to be included here; same token, there is a high proportion of participants (7.9%) with a self-reported diagnosis of asthma. At the population level there are no studies that quantify the so-called ‘clinical COPD’, as the thresholds to determine which symptoms and which exposures define it are even more diffuse than those of airflow limitation. Therefore, for consistency with the design of other epidemiological studies on COPD internationally (BOLD,<sup>8</sup> etc.) and the previous ones in Spain (IBERPOC,<sup>5</sup> EPISCAN<sup>6</sup>) the same design is maintained.

#### Future perspective

Better defining and grading obstructive airway diseases, and COPD in particular, is a long quest.<sup>43</sup> The GOLD initiative has

been modifying definitions, thresholds of spirometry and staging classifications in its several iterations.<sup>2</sup> New, recent evidence from COPDGene proposed the combination of four COPD domains: environmental exposure (cigarette smoking), clinical symptoms (dyspnoea and/or chronic bronchitis), chest CT imaging abnormalities, and abnormal spirometry; this new staging was strongly associated with spirometric disease progression (FEV<sub>1</sub> > 350 ml loss over 5 years), and all-cause mortality.<sup>44</sup> We strongly believe that the COPDGene proposal of possible, probable, and definite COPD will help to advance COPD research and medicine, just as a similar proposal with symptoms, EKG, enzymes helped ischaemic heart disease previously.

We conclude that COPD remains a major, common cause of disease in the general population, yet with substantial variability by age, sex, and geography, among other determinants. There is significant unmet need of airflow limitation at the individual and population levels. Last but not least, efforts to reduce COPD under-diagnosis, and the toll of cigarettes and of other old and new ways of smoking, should be streamlined.

## Funding

EPISCAN II is a GSK sponsored study.

## Conflict of interest

Individual ICJME forms are appended to this submission.

## Appendix A. Principal investigators, collaborators and participating centres

CC. AA.	CENTRE	INVESTIGATOR TEAM
MADRID	H. La Princesa	Julio Ancochea Bermudez (IP) / Elena García Castillo / Claudia Valenzuela / Joan B Soriano
CASTILLA LEÓN	H. U. de Burgos	Ana Pueyo Bastida (IP) / Lourdes Lázaro Asegurado / Luis Rodríguez Pascual / M <sup>l</sup> José Mora
ARAGÓN	H. Gral. San Jorge	Luis Borderías Clau (IP) / Lourdes Arizón Mendoza / Sandra García
EXTREMADURA	H. San Pedro de Alcántara	Juan Antonio Riesco Miranda (IP) / Julián Grande Gutiérrez / Jesús Agustín Manzano / Manuel Agustín Sojo González
CASTILLA LEÓN	H. Clínico U. de Salamanca	Miguel Barrueco Ferrero (IP) / Milagros Rosales
GALICIA	H. Álvaro Cunqueiro	José Alberto Fernández Villar (IP) / Cristina Represas / Ana Priegue / Isabel Portela Ferreiro / Cecilia Mouronte Roibás / Sara Fernández García
I. BALEARES	H. Son Espases	Borja G Cosío (IP) / Rocío Cordova Díaz / Nuria Toledo Pons / Margalida Llabrés
ARAGÓN	H. U. Miguel Servet	José María Marín Trigo (IP) / Marta Forner / Begoña Gallego / Pablo Cubero / Elisabet Vera
C. VALENCIANA	H. Arnau de Vilanova (Valencia)	Juan José Soler Cataluña (IP) / M <sup>l</sup> Begoña Picurelli Albero / Noelia González García
ANDALUCÍA	H. Virgen de la Macarena	Agustín Valido Morales (IP) / Carolina Panadero / Cristina Benito Bernáldez / Laura Martín -Bejarano y María Velarde (enfermeras sin acceso web)

CC. AA.	CENTRE	INVESTIGATOR TEAM
MURCIA	H. Gral. U. Santa Lucía (Cartagena)	Antonio Santa Cruz Siminiani (IP) / Carlos Castillo Quintanilla / Rocío Ibáñez Meléndez / José Javier Martínez Garcerán / Desirée Lozano Vicente / Pedro García Torres / Maria del Mar Valdivia
NAVARRA	Clínica Universidad de Navarra	Juan Pablo de Torres Tajés (IP) / Montserrat Cizur Girones / Carmen Labiano Turrillas
LA RIOJA	H. de San Pedro (Logroño)	Carlos Ruiz Martínez (IP) / Elena Hernando / Elvira Alfaro / José Manuel García / Jorge Lázaro
PAÍS VASCO	H. Santiago Apóstol (H. Txagorritxu)	David Bravo (IP) / Laura Hidalgo / Silvia Francisco Terreros / Iñaki Zorrilla / Ainara Alonso Colmenero /
ASTURIAS	H. Central de Asturias	Cristina Martínez González (IP) / Susana Margon / Rosirys Guzman Taveras / Ramón Fernández / Alicia Álvarez
CANTABRIA	H. de Valdecilla (Servicio de Neumología en el H. Santa Cruz de Liencres)	José Ramón Agüero Balbín (IP) / Juan Agüero Calvo
CATALUÑA	H. U. Vall d'Hebron	Jaume Joan Ferrer Sancho (IP) / Esther Rodríguez González / Eduardo Loeb
CASTILLA LA MANCHA	H. U. de Guadalajara	José Luis Izquierdo Alonso (IP) / M <sup>l</sup> Antonia Rodríguez García
I. CANARIAS	H. U. de Tenerife	Juan Abreu González (IP) / Candelaria Martín García / Rebeca Muñoz / Haydée Martín García
ASTURIAS	H. U. de San Agustín (Avilés):	Miguel Angel Martínez Muñoz (IP) / Andrés Avelino Sánchez Antuña / Jesús Allende González / Jose Antonio Gullón Blanco / Fernando José Alvarez Navascues / Manuel Angel Villanueva Montes / María Rodríguez Pericacho / Concepción Rodríguez García / Juan Diego Alvarez Mavárez

## References

- 2019 GOLD Report. Global strategy for prevention, diagnosis and management of COPD. <https://goldcopd.org> [accessed 3.03.19].
- Vogelmeier CF, Criner GJ, Martínez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al. Global strategy for the diagnosis management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary. *Arch Bronconeumol.* 2017;53:128–49.
- Miravittles M, Soler-Cataluña JJ, Calle M, Molina J, Almagro P, Quintano JA, et al. Spanish Guidelines for Management of Chronic Obstructive Pulmonary Disease (GesEPOC) 2017. Pharmacological treatment of stable phase. *Arch Bronconeumol.* 2017;53:324–35.
- Soriano JB, Zielinski J, Price D. Screening for and early detection of chronic obstructive pulmonary disease. *Lancet.* 2009;374:721–32.
- Sobradillo-Peña V, Miravittles M, Gabriel R, Jiménez-Ruiz CA, Villasante C, Masa JF, et al. Geographic variations in prevalence and underdiagnosis of COPD: results of the IBERPOC multicentre epidemiological study. *Chest.* 2000;118:981–9.
- Miravittles M, García-Río F, Muñoz L, Duran-Tauleria E, Sánchez G, Sobradillo V, et al. Prevalence of COPD in Spain: impact of undiagnosed COPD on quality of life and daily life activities. *Thorax.* 2009;64:863–8.
- Menezes AM, Perez-Padilla R, Jardim JR, Muño A, Lopez MV, Valdivia G, et al. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. *Lancet.* 2005;366:1875–81.
- López Varela MV, Montes de Oca, Halbert R, Muño A, Tálamo C, Pérez-Padilla R, et al. Comorbilidades y estado de salud en individuos con y sin EPOC en 5 ciudades de América Latina: Estudio PLATINO. *Arch Bronconeumol.* 2013;49:468–74.
- Soriano JB, Miravittles M. Datos epidemiológicos de EPOC en España. *Arch Bronconeumol.* 2007;43 Suppl. 1:2–9.
- Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet.* 2012;380:2095–128.
- GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with



- disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet Respir Med* 2017;5:691–706.
12. GBD Chronic Respiratory Disease Collaborators. Prevalence and attributable health burden of chronic respiratory diseases, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet Respir Med*. 2020;8:585–96.
  13. Alfageme I, de Lucas P, Ancochea J, Miravittles M, Soler-Cataluña JJ, García-Río F, et al. 10 years after EPISCAN: a new study on the prevalence of COPD in Spain – a summary of the EPISCAN II protocol. *Arch Bronconeumol*. 2019;55:38–47.
  14. Data protection in the EU. Regulation (EU) 2016/679. [https://ec.europa.eu/info/law/law-topic/data-protection/data-protection-eu\\_en](https://ec.europa.eu/info/law/law-topic/data-protection/data-protection-eu_en) [accessed 25.03.19].
  15. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening of Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *Lancet*. 2007;370:1453–7.
  16. García-Río F, Calle M, Burgos F, Casan P, Del Campo F, Galdiz JB, et al. Sociedad Española de Neumología y Cirugía Torácica (SEPAR) Espirometría. Sociedad Española de Neumología y Cirugía Torácica (SEPAR). *Arch Bronconeumol*. 2013;49:388–401.
  17. Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. ERS Global Lung Function Initiative Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations. *Eur Respir J*. 2012;40:1324–43.
  18. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. ATS/ERS Task Force Standardisation of spirometry. *Eur Respir J*. 2005;26:319–38.
  19. Charlson ME, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. *J Clin Epidemiol*. 1994;47:1245–51.
  20. de Torres JP, Casanova C, Marin JM, et al. Prognostic evaluation of COPD patients: GOLD 2011 versus BODE and the COPD comorbidity index COTE. *Thorax*. 2014;69:799–804.
  21. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. *N Engl J Med*. 2004;350:1005–12.
  22. Censos de Población y Viviendas 2011. [https://www.ine.es/censos2011\\_datos/cen11\\_datos\\_inicio.htm](https://www.ine.es/censos2011_datos/cen11_datos_inicio.htm) [accessed 10.12.19].
  23. Blanco I, Diego I, Bueno P, Fernández E, Casas-Maldonado F, Esquinas C, et al. Geographical distribution of COPD prevalence in Europe, estimated by an inverse distance weighting interpolation technique. *Int J Chron Obstruct Pulmon Dis*. 2017;13:57–67.
  24. Pearce N, Sunyer J, Cheng S, Chinn S, Björkstén B, Burr M, et al. Comparison of asthma prevalence in the ISAAC and the ECRHS ISAAC Steering Committee and the European Community Respiratory Health Survey. *International Study of Asthma and Allergies in Childhood*. *Eur Respir J*. 2000;16:420–6.
  25. Koo D, Thacker SB. In Snow's footsteps: commentary on shoe-leather and applied epidemiology. *Am J Epidemiol*. 2010;172:737–9.
  26. Soriano JB. The evolution of COPD species; or, something is changing for good in COPD. *Eur Respir J*. 2019;53.
  27. Soriano JB, Ancochea J, Miravittles M, García-Río F, Duran-Tauleria E, Muñoz L, et al. Recent trends in COPD prevalence in Spain: a repeated cross-sectional survey 1997–2007. *Eur Respir J*. 2010;36:758–65.
  28. Topalovic M, Das N, Burgel PR, Daenen M, Derom E, Haenebalcke C, et al. Artificial intelligence outperforms pulmonologists in the interpretation of pulmonary function tests. *Eur Respir J*. 2019;53.
  29. Brandt AM. The cigarette century: the rise, fall, and deadly persistence of the product that defined America. New York: Basic Books; 2009.
  30. Soriano JB, Rojas-Rueda D, Alonso J, Antó JM, Cardona PJ, Fernández E, et al. Colaboradores de GBD en España; Lista de colaboradores de GBD en España The burden of disease in Spain: Results from the Global Burden of Disease 2016. *Med Clin (Barc)*. 2018;151:171–90.
  31. Kalininskiy A, Bach CT, Nacca NE, Ginsberg G, Marraffa J, Navarette KA, et al. E-cigarette, or vaping, product use associated lung injury (EVALI): case series and diagnostic approach. *Lancet Respir Med*. 2019;7:1017–26.
  32. Fernández E, López MJ, Gallus S, Sempere S, Clancy L, Behrakis P, et al. TackSHS Project Investigators; TackSHS Project Investigators Tackling second-hand exposure to tobacco smoke and aerosols of electronic cigarettes: the TackSHS project protocol. *Gac Sanit*. 2019, pii: S0213-9111(19)30167-0.
  33. Soler-Cataluña JJ, Novella L, Soler C, Nieto ML, Esteban V, Sánchez-Toril F, et al. Clinical characteristics and risk of exacerbations associated with different diagnostic criteria of asthma-COPD overlap. *Arch Bronconeumol*. 2020;56:282–90.
  34. Wan ES, Fortis S, Regan EA, Hokanson J, Han MK, Casaburi R, et al. Longitudinal phenotypes and mortality in preserved ratio impaired spirometry in the COPD Gene study. *Am J Respir Crit Care Med*. 2018;198:1397–405.
  35. Lamprecht B, Soriano JB, Studnicka M, Kaiser B, Vanfleteren LE, Gnatiuc L, et al. Determinants of underdiagnosis of COPD in national and international surveys. *Chest*. 2015;148:971–85.
  36. Almagro P, Soriano JB. Underdiagnosis in COPD: a battle worth fighting. *Lancet Respir Med*. 2017;5:367–8.
  37. Ancochea J, Miravittles M, García-Río F, Muñoz L, Sánchez G, Sobradillo V, et al. Underdiagnosis of chronic obstructive pulmonary disease in women: quantification of the problem, determinants and proposed actions. *Arch Bronconeumol*. 2013;49:223–9.
  38. Ancochea J, Soriano JB. La epoc en España al inicio de una nueva década. *Arch Bronconeumol*. 2020, <http://dx.doi.org/10.1016/j.arbres.2020.01.025>. S0300-2896(20)30057-0. Online ahead of print.
  39. Bertens LC, Reitsma JB, van Mourik Y, Lammers JW, Moons KG, Hoes AW, et al. COPD detected with screening: impact on patient management and prognosis. *Eur Respir J*. 2014;44:1571–8.
  40. Poels PJ, Schermer TR, Schellekens DP, Akkermans RP, de Vries Robbé PF, Kaplan A, et al. Impact of a spirometry expert system on general practitioners' decision making. *Eur Respir J*. 2008;31:84–92.
  41. Llordés M, Jaén A, Almagro P, Heredia JL, Morera J, Soriano JB, et al. Prevalence risk factors and diagnostic accuracy of COPD among smokers in primary care. *COPD*. 2015;12:404–12.
  42. Christensen K, Doblhammer G, Rau R, Vaupel JW. Ageing populations: the challenges ahead. *Lancet*. 2009;374:1196–208.
  43. Barnes PJ, Vestbo J, Calverley PM. The pressing need to redefine "COPD". *Chronic Obstr Pulm Dis*. 2019;6:380–3.
  44. Lowe KE, Regan EA, Anzueto A, Austin E, Austin JHM, Beaty TH, et al. COPD Gene® 2019 redefining the diagnosis of chronic obstructive pulmonary disease. *Chronic Obstr Pulm Dis*. 2019;6:384–99.